Nanoparticles for use in immunogenic compositions
Disclosed herein are sterile-filtered lyophilized nanoparticle compositions which contain at least one biodegradable polymer, at least one surfactant, at least one cryoprotective agent and at least one antigen. Also disclosed are methods of making and using such compositions and kits supplying such compositions.
1. A sterile filtered lyophilized nanoparticle composition comprising (a) a biodegradable polymer, (b) a surfactant, (c) a cryoprotective agent, and (d) an antigen, wherein the composition does not comprise a polyoxyethylene block co-polymer and wherein the cryoprotective agent is present in an effective amount to allow for particle resuspension without aggregation.
2. The composition of claim 1 , wherein upon mixing lyophilized nanoparticle compositions of the present invention with distilled water in a concentration of 0.005 g/ml, an immunogenic nanoparticle suspension is spontaneously formed in which the Z average particle size of said suspended nanoparticles is less than 250 nm.
3. The composition of claim 1 or claim 2 , wherein the Z average particle size of said suspended nanoparticles is less than 200 nm.
4. The composition claim 1 , wherein the Z average particle size of said suspended nanoparticles is less than 150 nm.
5. The composition of claim 1 , wherein said surfactant is poly(vinyl alcohol).
6. The composition of claim 1 , wherein said surfactant is dioctyl sodium sulfosuccinate.
7. The composition of claim 1 , wherein the antigen comprises a polypeptide containing antigen.
8. The composition of claim 1 , wherein the antigen comprises a subunit antigen.
9. The composition of claim 1 , wherein the antigen comprises a polysaccharide-containing antigen.
10. The composition of claim 1 , wherein the antigen comprises a conjugate antigen.
11. The composition of claim 1 , wherein the antigen comprises a polynucleotide-containing antigen.
12. The composition of claim 11 , wherein the polynucleotide-containing antigen comprises a vector construct that encodes a polypeptide-containing antigen.
13. The composition of claim 1 , wherein the antigen comprises a tumor-cell-derived antigen.
14. The composition of claim 1 , wherein the antigen comprises a pathogenic-organism-derived antigen.
15. The composition of claim 14 , wherein the antigen is derived from a pathogenic organism selected from a virus, a bacterium, a fungus and a parasite.
16. The composition of claim 14 , wherein the antigen is derived from a pathogenic organism selected from hepatitis virus, varicella, poliovirus, measles, mumps, rubella, influenza virus, Neisseria meningitidis , pertussis, Haemophilus influenzae type b, human immunodeficiency virus (HIV), and Streptococcus pneumoniae.
17. The composition of claim 1 , wherein the antigen is adsorbed on the surfaces of the nanoparticles.
18. The composition of claim 1 , wherein the antigen is entrapped within the nanoparticles.
19. The composition of claim 1 , further comprising an immunological adjuvant.
20. The composition of claim 19 , wherein the immunological adjuvant is adsorbed to the surface of the suspended nanoparticles.
21. The composition of claim 19 , wherein the immunological adjuvant is entrapped within the suspended nanoparticles.
22. The composition of claim 19 , wherein the immunological adjuvant is selected from CpG oligonucleotides, double-stranded RNA, E. coli heat-labile toxins, alum, liposaccharide phosphate compounds, and liposaccharide phosphate mimetics.
23. The composition of claim 1 , wherein said immunogenic composition is sterilized by filtration prior to lyophilization.
24. A method of stimulating an immune response in a vertebrate host, comprising: combining the composition of claim 1 with an aqueous fluid to form a suspension; and administering the suspension to the host in an amount effective to induce an immune response.
25. The method of claim 24 , wherein said suspension is injected into said vertebrate host.
26. The method of claim 24 , wherein said vertebrate host is a human.
27. The method of claim 24 , wherein the immune response comprises a cellular immune response.
28. The method of claim 24 , wherein the immune response comprises a Th1 immune response.
29. The method of claim 24 , wherein the immune response comprises a CTL immune response.
30. The method of claim 24 , wherein the immune response is raised against a viral, bacterial, fungal or parasitic infection.
31. A method of immunizing a vertebrate host against a tumor or a pathogenic organism, comprising: combining the composition of claim 1 with an aqueous fluid to form a suspension; and administering the suspension to the host in an amount effective to induce a′ protective response.
32. A method of treating a tumor or a pathogenic organism infection in a vertebrate host, comprising: combining the composition of claim 1 with an aqueous fluid to form a suspension; and administering the suspension to the host in an amount effective to induce a treatment response.
33. A method of producing the composition of claim 1 , comprising: (a) combining (i) a first liquid that comprises said biodegradable polymer dissolved in an organic solvent with (ii) a second liquid that comprises water, whereupon a suspension of nanoparticles comprising said biodegradable polymer is formed, (b) adsorbing said antigen to said nanoparticles to form an antigen-adsorbed nanoparticle suspension, and (c) lyophilizing said antigen-adsorbed nanoparticle suspension.
34. The method of claim 33 , wherein said cryoprotective agent is added immediately prior to lyophilization.
35. The method of claim 33 , further comprising sterile filtering said nanoparticle suspension and said antigen prior to adsorbing said antigen to said nanoparticles.
36. The method of claim 33 , further comprising sterile filtering said antigen-adsorbed nanoparticle suspension prior to lyophilization.
37. A kit comprising a first container comprising the lyophilized nanoparticle composition of claim 1 .
38. The kit of claim 37 , further comprising a second container comprising a sterile liquid medium useful to resuspend the lyophilized nanoparticle composition in the first container.
39. The kit of claim 37 , further comprising a syringe.
40. The composition of claim 1 , wherein the antigen is selected from a pathogenic-organism-derived antigen and a tumor-cell-derived antigen.
41. The composition of claim 1 , wherein the cryoprotective agent comprises a saccharide.
42. The composition of claim 41 , wherein said saccharide is trehalose.
43. The composition of claim 41 , wherein said saccharide is sucrose.
44. The composition of claim 1 , wherein the cryoprotective agent comprises an alditol.
45. The composition of claim 44 , wherein said alditol is mannitol and wherein said surfactant is selected from an anionic surfactant and a non-ionic surfactant.
46. The composition of claim 44 , wherein said alditol is mannitol and wherein said surfactant is a non-ionic surfactant.
47. A sterile filtered lyophilized nanoparticle composition comprising (a) a biodegradable polymer selected from a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, a polycyanoacrylate and combinations thereof, (b) a surfactant, (c) a cryoprotective agent, and (d) an antigen, wherein the crvoprotective agent is present in an effective amount to allow for particle resuspension without aggregation.
48. The composition of claim 47 , wherein the composition comprises the poly(α-hydroxy acid) and the poly(α-hydroxy acid) is selected from poly(lactide), poly(glycolide), poly(lactide-co-glycolide) and combinations thereof.
49. The composition of claim 48 , wherein the composition comprises the poly(lactide-co-glycolide) and the poly(lactide-co-glycolide) has a lactide:glycolide molar ratio ranging from 40:60 to 60:40.